Chemotherapy for Malignant Disease

Description of Procedure or Service

Chemotherapy is a cancer treatment that uses chemical agents to kill cancer cells. The chemicals have a specific toxic effect upon cancer cells. They either destroy them or prevent the malignant cells from multiplying. The chemotherapy drugs may also have the same effect on normal cells. Administration of the drugs requires close monitoring for toxicity levels and for the patient’s response to therapy. Chemotherapy may be used in the following ways:

- As a first line therapy for advanced malignant disease,
- As an adjunct to local treatment, i.e., following surgery to remove the malignancy,
- As a primary treatment for localized malignant disease,
- For direct instillation to the site affected by the malignant disease.

Please note that for the purpose of BCBSNC policy, the Food and Drug Administration’s (FDA) approval means full, unrestricted market approval. Off-labeled indications (using a drug for a purpose other than what the FDA approved it for) may also be covered. Please see “Policy” below for medical guidelines for when off-labeled use may be covered.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

BCBSNC covers Chemotherapeutic drugs when they are considered medically necessary because the criteria listed below have been met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member’s benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Chemotherapy for Malignant Disease is covered

When both of the following criteria are met:
1. The drug must be approved by the FDA
Chemotherapy for Malignant Disease

2. The drug must have been proven effective and accepted for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia:
   a. The National Comprehensive Cancer Network Drugs & Biologics Compendium,
   b. The ThomsonMicromedex DrugDex,
   c. The Elsevier Gold Standard’s Clinical Pharmacology, or
   d. Any other authoritative compendia as recognized periodically by the United States Secretary of Health and Human Services.

***Note: Once a particular chemotherapeutic drug has received full and unrestricted FDA market approval, the Plan will provide benefits for additional indications (“off label use”) when an additional indication is recognized by any one of the reference compendia listed above and has shown to be effective and accepted for treatment of the cancer for which it has been prescribed.

When Chemotherapy for Malignant Disease is not covered

1. when the appropriate FDA approval has not been granted (See Description of Service.)
2. when the chemotherapeutic drug is not listed in one of the above medical reference sources
3. when the chemotherapeutic drug has not proven to be an effective or accepted treatment for the diagnosis for which administration of the chemotherapeutic drug is anticipated.

Policy Guidelines

The NC state statute 58-51-59 states “coverage shall not be required for any experimental or investigational drugs or any drug that the Federal Food and Drug Administration has determined to be contraindicated for treatment of the specific type of cancer for which the drug has been prescribed.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 96401, 96402, 96405, 96406, 96409, 96411, 96413, 96415, 96416, 96417, 96420, 96422, 96423, 96425, 96440, 96450, 96542, 96549, G0498

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

Senior Director, Medical Affairs
Chemotherapy for Malignant Disease

Certificate provisions defining investigational.

North Carolina General Statutes: 58-51-59


Medical Policy Advisory Group 12/2/1999


Senior Medical Director 6/2009


North Carolina General Statutes: 58-51-59


Policy Implementation/Update Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/96</td>
<td>Revised: Clarification of policy guidelines</td>
</tr>
<tr>
<td>10/96</td>
<td>Revised: Added General Statutes identification number</td>
</tr>
<tr>
<td>1/98</td>
<td>Revised: Removed statements regarding review of medical literature by Medical Director when additional indications for use are not found in the 3 compendia. Added statement from the NC general statutes regarding indications not found to be safe and effective or that have been contraindicated by the FDA.</td>
</tr>
<tr>
<td>11/98</td>
<td>Revised: Removed statement “Plan Pharmacist is to refer the case to Medical Affairs for review by the Medical Director.” Replaced with “the case should be referred back to the referring Medical Director for denial.</td>
</tr>
<tr>
<td>6/99</td>
<td>Reformatted, “Description of Procedure or Service” revised, Medical Term Definitions added.</td>
</tr>
<tr>
<td>12/99</td>
<td>Reaffirmed, Medical Policy Advisory Panel</td>
</tr>
</tbody>
</table>
Chemotherapy for Malignant Disease

7/00  System coding changes.


11/03  Specialty Matched Consultant Advisory Panel review. Updated Benefit Application and Billing and Coding sections of the policy. No change to criteria.

10/8/05  Specialty Matched Consultant Advisory Panel review 9/19/2005. No changes to criteria. Policy status changed to "Active policy, no longer scheduled for routine review." References added.

1/5/06  Added new 2006 CPT codes 96401, 96402, 96409, 96411, 96413, 96415, 96416, 96417, and 96420 to the "Billing/Coding" section. Removed deleted CPT codes 96400, 96408, 96410, 96412, and 96414.


6/22/10  Policy Number(s) removed (amw)

9/30/11  No changes to policy. Consistent with North Carolina State Mandate. Specialty Matched Consultant Advisory Panel review August 31, 2011. (btw)

9/4/12  No change to policy. Continues to be consistent with North Carolina Mandate. (btw)

10/13/12  Removed deleted CPT code, 96445, from Billing/Coding section. (btw)

9/10/13  Specialty Matched Consultant Advisory Panel review 8/21/2013. No change to policy. Policy continues to be consistent with North Carolina Mandate. (btw)

9/9/14  Specialty matched consultant advisory panel review 8/26/2014. No changes to policy. Policy continues to be consistent with North Carolina Mandate. (lpr)

10/1/15  Specialty Matched Consultant Advisory Panel review 8/26/2015. Policy continues to be consistent with North Carolina Mandate. No changes to policy statement. (lpr)

9/30/16  Specialty Matched Consultant Advisory Panel review 8/31/2016. Added HCPC code G0498 to Billing/Coding section. No change to policy statement. (lpr)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.